Trastuzumab in combination with chemotherapy is the current first-line treatment option for HER2-positive advanced GC, and ramucirumab alone or in combination with paclitaxel as well as apatinib mesylate are also recommended as second- or third-line treatment options for advanced GC (40–43). The gene discussed is ERBB2; the disease is gastric cancer.